Short answer
MAXCYTE, INC. (MXCT) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026 announced August 12, 2026.
MAXCYTE, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced August 12, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
- Disclosure furnished, not filed under Exchange Act Section 18 liability provisions
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation posted August 12, 2026 for investor communications and conferences
- Exhibit 99.2 contains management’s latest corporate messaging and strategy context
- Disclosure furnished under Regulation FD, not filed under Section 18 liability standards
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $7.3M, down 15% YoY; core revenue $6.5M, down 21%, signaling continued operating softness
- SPL revenue rose to $0.8M from $0.3M, driven by royalties up 150% to $0.8M
- Gross margin fell to 77% from 82%, while adjusted core margin declined to 77% from 83%
- Net loss improved to $8.9M from $12.4M as operating expenses fell to $15.8M from $21.2M
- 2026 guidance reiterated at $30M-$32M revenue and at least $130.5M ending cash, excluding further buybacks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MAXCYTE, INC. 8-K filings
Get the next MXCT 8-K as it lands
Follow MXCT for push alerts, or ask the research agent what this filing means.